Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Iralukast is a cysteinyl-leukotriene antagonist (CysLT) with a pKi of 7.8 for CysLT1.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 4,070.00 | |
50 mg | 10-14 weeks | $ 5,380.00 | |
100 mg | 10-14 weeks | $ 7,600.00 |
Description | Iralukast is a cysteinyl-leukotriene antagonist (CysLT) with a pKi of 7.8 for CysLT1. |
In vitro | Both Iralukast and CGP 57698 are able to compete for the two sites labelled by [3H]-LTD4. As in all the G-protein coupled receptors, Iralukast and CGP 57698 do not discriminate between the high and the low affinitystates of the CysLT receptor labelled by LTD4 (Ki1=Ki2=16.6 nM±36% CV and Ki1=Ki2=5.7 nM±19% CV, respectively). Iralukast, displays a slow bindingkinetic, because preincubation (15 min) increases its antagonist potency. Iralukast and CGP 57698 antagonize LTD4-induced contraction of humanbronchi, with pA2 values of 7.77±4.3% CV and 8.51±1.6% CV, respectively, and slopes not significantly different from unity[2]. |
Molecular Weight | 710.76 |
Formula | C38H37F3O8S |
CAS No. | 151581-24-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Soluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Iralukast (CGP 45715A) 151581-24-7 Iralukast CGP 45715A inhibitor inhibit